Payment overview · 2025
General Payments
$125,045.84
235 reported records · 23 companies
Healthcare provider profile · identity verified
Jay E Gladstein, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease · LOS ANGELES, CA · NPI 1154428613
Verified facts
What the public records show
CMS Open Payments records show Jay E Gladstein, M.D. received $125,045.84 in general payments during 2025 across 235 reported records.
Gilead Sciences, Inc. accounted for 58.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Cabenuva, Descovy, Dovato, Mounjaro, Pifeltro, Xyosted.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
Antares Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYOSTED as an associated drug or biological on 18015 records involving 7619 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Xyosted by this doctor in 2024.
EMD Serono, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Serostim as an associated drug or biological on 153 records involving 74 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Serostim by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 406 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Descovy by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMTUZA as an associated drug or biological on 44 records involving 34 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symtuza by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISENTRESS as an associated drug or biological on 37 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Isentress by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PIFELTRO as an associated drug or biological on 7921 records involving 2912 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Pifeltro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ozempic by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CABENUVA as an associated drug or biological on 13941 records involving 3305 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Cabenuva by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $73,283.16 | 58.6% | 84 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $50,423.13 | 40.3% | 100 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $312.36 | 0.2% | 11 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $127.80 | 0.1% | 4 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $115.68 | 0.1% | 3 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $79.96 | 0.1% | 4 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $74.48 | 0.1% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $74.00 | 0.1% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $71.39 | 0.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $68.11 | 0.1% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $55.17 | 0.0% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $40.38 | 0.0% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $39.94 | 0.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $39.87 | 0.0% | 2 | 2025 |
| Theratechnologies Inc. | Unresolved — no canonical attribution shown | $34.94 | 0.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.39 | 0.0% | 2 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.13 | 0.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.14 | 0.0% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $28.48 | 0.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.74 | 0.0% | 1 | 2025 |
| Napo Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $21.34 | 0.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.84 | 0.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.41 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $89,085.00 | 28 |
| Consulting Fee | $16,920.00 | 5 |
| Travel and Lodging | $11,456.10 | 31 |
| Food and Beverage | $7,584.74 | 171 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $44,837.77 | 44 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $28,872.07 | 23 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $22,942.05 | 23 | 2025 |
Source payment records
|
|||||
| Descovy Normalized: descovy |
Drug | Gilead Sciences, Inc. | $13,764.10 | 9 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $395.11 | 17 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $392.11 | 13 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $312.36 | 11 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $127.80 | 4 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $79.96 | 4 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $74.48 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $74.00 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $68.11 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $68.11 | 3 | 2025 |
Source payment records
|
|||||
| RUKOBIA Normalized: rukobia |
Drug | ViiV Healthcare Company | $62.10 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $55.17 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $44.62 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $44.62 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $40.38 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $39.94 | 1 | 2025 |
Source payment records
|
|||||
| EGRIFTA Normalized: egrifta |
Drug | Theratechnologies Inc. | $34.94 | 1 | 2025 |
Source payment records
|
|||||
| TROGARZO Normalized: trogarzo |
Drug | Theratechnologies Inc. | $34.94 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $33.13 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.14 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.14 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $28.48 | 1 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $26.77 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.74 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.45 | 1 | 2025 |
Source payment records
|
|||||
| Mytesi Normalized: mytesi |
Drug | Napo Pharmaceuticals Inc | $21.34 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 406 | exact normalized | Medicare Part D |
| CABENUVA cabenuva |
2025 | Cabenuva | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Descovy descovy |
2025 | Descovy | 2024 | 54 | exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PIFELTRO pifeltro |
2025 | Pifeltro | 2024 | 80 | exact normalized | Medicare Part D |
| XYOSTED xyosted |
2025 | Xyosted | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Antares Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | XYOSTED open payments reported associated product |
CMS Open Payments — General Payments 18015 supporting records · 7619 recipient NPIs · example record 1235880452 |
Xyosted · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| EMD Serono, Inc. Exact reporting entity; no affiliate inference |
2025 | Serostim open payments reported associated product |
CMS Open Payments — General Payments 153 supporting records · 74 recipient NPIs · example record 1236871463 |
Serostim · 2024 Exact normalized brand match · 1 Part D row |
82 | 12 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
406 | 68 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
54 | 17 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | SYMTUZA open payments reported associated product |
CMS Open Payments — General Payments 44 supporting records · 34 recipient NPIs · example record 1174329506 |
Symtuza · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | ISENTRESS open payments reported associated product |
CMS Open Payments — General Payments 37 supporting records · 24 recipient NPIs · example record 1238003286 |
Isentress · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | PIFELTRO open payments reported associated product |
CMS Open Payments — General Payments 7921 supporting records · 2912 recipient NPIs · example record 1237992198 |
Pifeltro · 2024 Exact normalized brand match · 1 Part D row |
80 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | CABENUVA open payments reported associated product |
CMS Open Payments — General Payments 13941 supporting records · 3305 recipient NPIs · example record 1189508908 |
Cabenuva · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 406 | 68 |
| Atorvastatin Calcium | Atorvastatin Calcium | 360 | 79 |
| Losartan Potassium | Losartan Potassium | 186 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 174 | 35 |
| Bupropion Xl | Bupropion Hcl | 173 | 26 |
| Valacyclovir | Valacyclovir Hcl | 152 | 30 |
| Tivicay | Dolutegravir Sodium | 136 | 27 |
| Testosterone Cypionate | Testosterone Cypionate | 132 | 26 |
| Omeprazole | Omeprazole | 123 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 113 | 19 |
| Amlodipine Besylate | Amlodipine Besylate | 110 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 110 | 23 |
| Testosterone | Testosterone | 103 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 21 |
| Meloxicam | Meloxicam | 96 | 21 |
| Finasteride | Finasteride | 88 | 19 |
| Gabapentin | Gabapentin | 87 | 17 |
| Serostim | Somatropin | 82 | 12 |
| Pifeltro | Doravirine | 80 | 14 |
| Lisinopril | Lisinopril | 77 | 22 |
| Alprazolam | Alprazolam | 75 | 18 |
| Trazodone Hcl | Trazodone Hcl | 75 | 14 |
| Ezetimibe | Ezetimibe | 72 | 14 |
| Levothyroxine Sodium | Levothyroxine Sodium | 61 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 55 | 24 |
| Jardiance | Empagliflozin | 55 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 54 | 17 |
| Famotidine | Famotidine | 54 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | suppressed |
| Metformin Hcl | Metformin Hcl | 52 | 14 |
| Eszopiclone | Eszopiclone | 50 | 11 |
| Clonazepam | Clonazepam | 46 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 46 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 45 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 43 | suppressed |
| Acyclovir | Acyclovir | 41 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 40 | suppressed |
| Trulicity | Dulaglutide | 40 | suppressed |
| Xyosted | Testosterone Enanthate | 40 | suppressed |
| Ketoconazole | Ketoconazole | 39 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 37 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 35 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 33 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Isentress | Raltegravir Potassium | 32 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Allopurinol | Allopurinol | 30 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 30 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | 13 |
| Praluent Pen | Alirocumab | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 28 | suppressed |
| Tadalafil | Tadalafil | 28 | suppressed |
| Vascepa | Icosapent Ethyl | 28 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | suppressed |
| Maraviroc | Maraviroc | 26 | suppressed |
| Minoxidil | Minoxidil | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Anastrozole | Anastrozole | 23 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Egrifta Sv | Tesamorelin Acetate | 21 | suppressed |
| Abacavir-Lamivudine | Abacavir Sulfate/Lamivudine | 20 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | 11 |
| Livalo | Pitavastatin Calcium | 20 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 20 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Lamivudine | Lamivudine | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Ozempic | Semaglutide | 18 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Veo Insulin Syringe | Syringe And Needle,insulin,1ml | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Darunavir | Darunavir | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Eliquis | Apixaban | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Cabenuva | Cabotegravir/Rilpivirine | 14 | suppressed |
| Carvedilol | Carvedilol | 14 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 14 | suppressed |
| Xifaxan | Rifaximin | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Furosemide | Furosemide | 13 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Cefadroxil | Cefadroxil | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Evotaz | Atazanavir Sulfate/Cobicistat | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Leflunomide | Leflunomide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $125,045.84 · 235 records | Gilead Sciences, Inc. | AIRSUPRA, APLENZIN, APRETUDE, Auvelity, Azstarys, Biktarvy, CABENUVA, CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, DOVATO, Descovy, EGRIFTA, GARDASIL 9, GEMTESA, INGREZZA, MOUNJARO, Mytesi, OTEZLA, PIFELTRO, REPATHA, RUKOBIA, SHINGRIX, SPRAVATO, TROGARZO, Tlando, VIVITROL, VRAYLAR, Wegovy, XYOSTED, Yeztugo, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error